RIPK1 and neoplasm: Our data provide a plausible explanation for why systemic administration of TNF failed as an effective therapy for malignancies: TNF must be delivered by tumor-reactive T cells during cognate interactions with the tumor targets in order to activate RIPK1-dependent cell death and tumor destruction.